Figure 7

Representative decrease in the number of MDSCs by Imatinib. (a) The spleen cells harvested from B10 mice were maintained in conditioned medium for 7 days to expand Gr-1⁺CD11b⁺ cells. Different doses of Imatinib (10, 20, and 30 ng/ml) were added to block the effect of SCF. The frequency of Gr-1⁺CD11b⁺ cells was decreased when 30 ng/ml Imatinib was added. (b) When EL4 tumors on the back of B6 mice was 5 × 5 mm in diameter, the mice were treated with Imatinib. The tumor growth in Imatinib-treated mice was slower than in control mice. On day 11 of treatment, the tumor volume was 927.7 ± 558.5 mm³ in the mice treated with Imatinib, compared to 2050.4 ± 282.7 mm³ in control mice (p = 0.023).